Blue Trust Inc’s Galectin Therapeutics GALT Stock Holding History

Blue Trust Inc’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$32.5K	Hold	7,000	–	–	﹤0.01%	1514
2026 Q1	$19.5K	Hold	7,000	–	–	﹤0.01%	1653
2025 Q4	$29.1K	Hold	7,000	–	–	﹤0.01%	1553
2025 Q3	$29.6K	Sell	7,000 -1,800	-20%	-$6.77K	﹤0.01%	1563
2025 Q2	$18.6K	Buy	8,800 +1,800	+26%	+$2.69K	﹤0.01%	1699
2025 Q1	$8.54K	Hold	7,000	–	–	﹤0.01%	1961
2024 Q4	$9.03K	Hold	7,000	–	–	﹤0.01%	1974
2024 Q3	$15.8K	Hold	7,000	–	–	﹤0.01%	2037
2024 Q2	$16.7K	Hold	7,000	–	–	﹤0.01%	1738
2024 Q1	$16.7K	Hold	7,000	–	–	﹤0.01%	1297
2023 Q4	$13K	Hold	7,000	–	–	﹤0.01%	1482
2023 Q3	$10K	Hold	7,000	–	–	﹤0.01%	1405
2023 Q2	$15K	Hold	7,000	–	–	﹤0.01%	1157
2023 Q1	$8K	Hold	7,000	–	–	﹤0.01%	1658
2022 Q4	$11K	Hold	7,000	–	–	﹤0.01%	1505
2022 Q3	$9K	Hold	7,000	–	–	﹤0.01%	1372
2022 Q2	$11K	Buy	+7,000	New	+$10.1K	﹤0.01%	1168

Other funds holding GALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Blue Trust Inc's GALT Position: Q2 2026 in Review

Blue Trust Inc held its Galectin Therapeutics (GALT) position steady in Q2 2026 at 7,000 shares worth $32.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1514.

Blue Trust Inc first reported a position in GALT in Q2 2022 and has held it in 17 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

Blue Trust Inc held 7,000 shares of Galectin Therapeutics worth $32.5K as of Q2 2026.
Blue Trust Inc left its Galectin Therapeutics share count unchanged in Q2 2026.
Galectin Therapeutics made up ﹤0.01% of Blue Trust Inc's portfolio in Q2 2026, its #1514 holding.
Blue Trust Inc first reported a position in Galectin Therapeutics in Q2 2022 and has held it in 17 quarters since.
98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Blue Trust Inc's 13F filing for Q2 2026, filed 21 Jul 2026.